Literature DB >> 9284706

Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects.

L Ramirez1, L E Braverman, B White, C H Emerson.   

Abstract

Recombinant human TSH (rhTSH) is known to stimulate 131I uptake and thyroglobulin (Tg) release from the postoperative remnant and metastases in thyroid cancer patients, but its effects on serum thyroid hormone and Tg concentrations in normal subjects have not been reported. Before using rhTSH in the management of thyroid disorders other than cancer, the thyroid response to rhTSH in normal subjects must be assessed. Six subjects, two men and four women, without evidence of thyroid disease, including normal serum free T4 index and TSH concentrations and negative tests for antithyroid peroxidase and Tg, were studied. Each received 0.1 mg rhTSH, im, 11% of the lowest dose that has been administered to thyroid cancer patients. Blood was obtained before; 2, 4, and 8 h after; and 1, 2, 3, 4, 7, and about 3 weeks after rhTSH administration. Serum TSH significantly increased at 2 h (mean +/- SE, 2.4 +/- 0.9 to 40.7 +/- 7.4 mU/mL), peaked at 4 h (50.9 +/- 9.3), remained significantly elevated for 1 day, and was significantly below baseline (0.8 +/- 0.5) 7 days after rhTSH administration. Serum T3 increased significantly at 4 h (115 +/- 4 to 190 +/- 14 ng/dL), peaked at 24 h (217 +/- 23 ng/dL), and remained significantly elevated for 3 days (151 +/- 12 ng/dL). Serum T4 increased significantly at 8 h (7.3 +/- 0.2 to 9.8 +/- 0.4 micrograms/dL), peaked at 24 h (11.2 +/- 0.5 micrograms/dL), and remained significantly elevated for 4 days (9.4 +/- 0.5 micrograms/dL). Serum Tg did not change for the first 8 h, increased significantly at 1 day (15.9 +/- 3.9 to 34.7 +/- 6.0 ng/mL), peaked at 2 days (44.2 +/- 7.0 ng/mL), and remained significantly elevated for 4 days (37.7 +/- 13.7 ng/mL). All values returned to baseline at 3 weeks. TSH antibodies were not detected at 3 weeks. A single dose of 0.1 mg rhTSH is a potent stimulator of thyroid function in normal subjects. rhTSH may be a useful agent to test thyroid reserve and for use in clinical settings that require direct thyroid stimulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284706     DOI: 10.1210/jcem.82.9.4205

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling.

Authors:  Rebecca A Sendak; T Kuber Sampath; John M McPherson
Journal:  Int Orthop       Date:  2007-07-05       Impact factor: 3.075

2.  Use of recombinant human thyroid-stimulating hormone for thyrotropin stimulation test in euthyroid dogs.

Authors:  F Sauvé; M Paradis
Journal:  Can Vet J       Date:  2000-03       Impact factor: 1.008

3.  The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production.

Authors:  M Luster; W Reinhardt; C Korber; M Lassmann; H Haenscheid; U Michalowski; J Rendl; E Eising; K Mann; C Reiners
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

4.  Inability of recombinant human thyrotropin to predict the evolution from subclinical hypothyroidism to overt disease. A pilot study.

Authors:  C Zafon; B Rodríguez; J B Montoro; D Cabo; J Mesa
Journal:  J Endocrinol Invest       Date:  2011-04-26       Impact factor: 4.256

Review 5.  An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter.

Authors:  Geraldo Medeiros-Neto; Suemi Marui; Meyer Knobel
Journal:  Endocrine       Date:  2008-05-20       Impact factor: 3.633

6.  Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis.

Authors:  Marisa Eisenberg; Mary Samuels; Joseph J DiStefano
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

7.  Use of recombinant human thyroid-stimulating hormone for thyrotropin stimulation test in healthy, hypothyroid and euthyroid sick dogs.

Authors:  Sylvie Daminet; Lyanne Fifle; Manon Paradis; Luc Duchateau; Maxim Moreau
Journal:  Can Vet J       Date:  2007-12       Impact factor: 1.008

8.  Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.

Authors:  I G S Rubio; M N C Silva; M Knobel; R Romão; R Possato; E M M S Gebrin; C Buchpiguel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

9.  Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism.

Authors:  Flore Duranton; Anouchka Lacoste; Patrick Faurous; Emmanuel Deshayes; Jean Ribstein; Antoine Avignon; Georges Mourad; Àngel Argilés
Journal:  Clin Kidney J       Date:  2013-09-01

10.  The Relationship between Population T4/TSH Set Point Data and T4/TSH Physiology.

Authors:  Stephen Paul Fitzgerald; Nigel Geoffrey Bean
Journal:  J Thyroid Res       Date:  2016-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.